Hidenao Noritake
Overview
Explore the profile of Hidenao Noritake including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morita Y, Oda K, Matsumoto A, Ida S, Kitajima R, Furuhashi S, et al.
Surg Case Rep
. 2025 Feb;
11(1).
PMID: 39974545
Introduction: Intrahepatic cholangiocarcinoma (ICC) is a highly malignant cancer for which surgery is the only curative treatment. The prognosis of ICC is extremely poor, especially in cases of lymph node...
2.
Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, et al.
Oncology
. 2025 Feb;
:1-23.
PMID: 39900019
Background/aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use of tumor markers as...
3.
Kitsugi K, Chida T, Hanaoka T, Umemura M, Yamashita M, Ito J, et al.
Mol Biol Rep
. 2024 Dec;
52(1):81.
PMID: 39722039
Background: Neprilysin (NEP) is a metalloprotease that has become a therapeutic target for the treatment of heart failure and hypertension. However, the significance of NEP in chronic liver diseases has...
4.
Danpanichkul P, Duangsonk K, Diaz L, Chen V, Rangan P, Sukphutanan B, et al.
Drug Alcohol Depend
. 2024 Nov;
266:112495.
PMID: 39603063
Background: Substance use disorders (SUDs) play a major role in global preventable disability and mortality. Even though they impact patients of all ages, adolescents and young adults (AYAs) are at...
5.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, et al.
Hepatol Res
. 2024 Nov;
PMID: 39526824
Aim: Since the development of tremelimumab plus durvalumab (Dur/Tre) for unresectable hepatocellular carcinoma (uHCC), it has been used as not only an initial but also later line treatment in clinical...
6.
Kitsugi K, Kawata K, Noritake H, Chida T, Ohta K, Ito J, et al.
Ann Med
. 2024 Sep;
56(1):2398725.
PMID: 39221763
Objectives: Although systemic chemotherapy for pancreatic ductal adenocarcinoma (PDAC) has made progress, ensuring long-term survival remains difficult. There are several reports on the usefulness of neutrophil-to-lymphocyte ratio (NLR) in predicting...
7.
Toyoda H, Fujii H, Iwaki M, Hayashi H, Oeda S, Hyogo H, et al.
Gastro Hep Adv
. 2024 Aug;
2(8):1093-1102.
PMID: 39131553
Background And Aims: Nonalcoholic fatty liver diseases (NAFLD) and nonalcoholic steatohepatitis (NASH) can cause hepatocellular carcinoma (HCC). We examined histological features and reported noninvasive markers/models for stratifying the risk of...
8.
Umemura M, Honda A, Yamashita M, Chida T, Noritake H, Yamamoto K, et al.
J Autoimmun
. 2024 Jul;
148:103287.
PMID: 39033687
Increasing evidence suggests that, in addition to a loss of tolerance, bile acid (BA) modulates the natural history of primary biliary cholangitis (PBC). We focused on the impacts of dietary...
9.
Chida T, Ohta K, Noritake H, Matsushita M, Murohisa G, Kageyama F, et al.
Sci Rep
. 2024 May;
14(1):10864.
PMID: 38740815
Lysyl oxidase-like 2 (LOXL2) mediates the crosslinking of extracellular collagen, reflecting qualitative changes in liver fibrosis. This study aimed to validate the utility of serum LOXL2 levels as a predictive...
10.
Nouso K, Kawanaka M, Fujii H, Kariyama K, Toyoda H, Iwaki M, et al.
Hepatol Res
. 2024 Apr;
54(10):912-920.
PMID: 38661715
Background And Aims: Because the accuracy of the Fibrosis-4 (FIB-4) index for predicting liver fibrosis changes with age, the need for different cut-offs in various age groups has frequently been...